eligibility_summary
Adults 18–75 with histologically confirmed RAS–wild-type colorectal adenocarcinoma, CRS≥3, synchronous liver-only metastases with ≥1 measurable lesion, WHO PS 0–1, life expectancy ≥3 months, adequate hematologic and liver/renal function, and consent. Exclude prior systemic/surgical metastatic therapy, extrahepatic mets, unresectable primary, recent major CV events, bowel obstruction, recent second cancer, substance abuse, legal incapacity, pregnancy/lactation, uncontrolled HTN, or neuropathy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Cetuximab (chimeric IgG1 anti‑EGFR monoclonal antibody) added to mFOLFOX6 chemotherapy (oxaliplatin, leucovorin, 5‑fluorouracil) versus mFOLFOX6 alone. Mechanisms: Cetuximab blocks EGFR ligand binding, suppressing downstream RAS‑RAF‑MEK‑ERK and PI3K‑AKT signaling, and can trigger ADCC. 5‑FU is an antimetabolite that inhibits thymidylate synthase and incorporates into RNA/DNA, leucovorin enhances 5‑FU’s TS binding, oxaliplatin is a platinum agent creating DNA crosslinks → apoptosis. Targets: EGFR‑dependent, RAS/BRAF wild‑type colorectal cancer cells in liver metastases, key pathways: EGFR signaling and DNA/nucleotide synthesis/repair.